Venturis Therapeutics, Inc. has 3 open IND’s with the US Food and Drug Administration and 4 preclinical programs. Each are discussed below:

Clinical Stage Programs

Drug Candidate
Indication
Status
CVBT-141 Vascu-Grow™
CD Foot Ulcers (Chronic Diabetic Foot Ulcers)
Phase 1
Phase 2
Phase 2
CVBT-141 Vascu-Grow™
CAD (Coronary Artery Disease)
CVBT-141 Vascu-Grow™
PAD (Peripheral Arterial Disease)

Pre-Clinical Research & Development

Drug Candidate
Indication
CVBT-141ED
CVBT-141S
Infarct Stroke
Erectile Dysfunction
CVBT-141D
Ischemic Disc Disease
CVBT-141P
Parkinson’s Disease